Background: Thiazole nucleus-containing compounds have an antitumor efficiency against various types of cancer. Purpose: The present study was designed to determine the cytotoxic effect of newly synthesized thiazole derivative (TD1) on human cancer cell lines, in addition to evaluate its antitumor activity against Ehrlich ascites carcinoma (EAC) in mice. Materials and Methods: TD1 was synthesized and investigated for its cytotoxic effect on HCT116 (colon cancer), HepG2 (liver cancer), PC3 (prostate cancer) and MCF7 (breast cancer). The effect of TD1 on cell viability, tumor volume, and percent of increase in life span (% ILS) in Ehrlich-bearing mice was studied. Hematological parameters, liver and kidney function tests were evaluated. The Faten et al.; AJRB, 3(2): 1-16, 2018; Article no.AJRB.46250 2 activity of superoxide dismutase (SOD) and catalase (CAT), as well as malondialdehyde (MDA) and reduced glutathione levels were determined in liver and kidney tissues. The expression of P 53 in EAC was analyzed by flow cytometry. Results: TD1 demonstrated an inhibitory effect on both cancer cell lines in vitro and Ehrlich ascites cells in vivo. TD1 increased in life span of Ehrlich-bearing mice compared to control. Cell cycle and flow cytometric analysis revealed that TD1 directed Ehrlich cells toward apoptosis by increasing of P 53 expression. Conclusion: It was concluded that TD1 have a potent antitumor activity against Ehrlich ascites carcinoma in mice beside a cytotoxic effect on MCF-7, PC3, HepG2 and HCT-116.
INTRODUCTION
Cancer is an abnormal proliferation of a group of cells which can metastasize in other body organs [1] . Cancer is the second cause of human death [2] . According to the American cancer society, about 569,490 Americans died due to cancer in 2010. The most common type in males is prostate cancer while in females the most common type is breast cancer [3] .
It has been shown that cancer develops as a consequence of genetic aberrations in a way that overrides the checks and balances of the cell. However, many cancers cannot be related to specific genes, and some genes may interact in unpredictable ways with other genes or factors in the environment to cause cancer [4] .
Thiazole derivatives are known to possess several biological activities including anticancer activity [5] . There are a variety of mechanisms for the antitumor action of thiazole derivatives, acting on cancer bio targets, such as tumor necrosis factor TNF-α [6] , inosine monophosphate dehydrogenase (IMPDH) [7] and apoptosis inducers [8] .
Multiple classes of thiazole derivatives such as Schiff bases, mono-, di-, tri-, and heterocyclic substituents that possess anticancer activity have been exemplified. Molecular modelling of compounds that predicts enhanced anticancer activity of the modified structures has also been elaborated in the review. Significant advancements in synthetic chemistry related to cytotoxicity can now better position the drug discovery team to undertake thiazoles as valuable leads. The beneficial thiazole derivatives possessing anticancer activity will reignite the interest of medicinal chemists in thiazole and their derivatives [9] .
The tumor suppressor protein, p53, regulates the cell cycle and thus functions as a tumor suppressor involved in cancer prevention. As such, p53 has been described as "the guardian of the genome", referring to its role in conserving stability by preventing genome mutation. It can activate DNA repair proteins when DNA has sustained damage. It can induce growth arrest by holding the cell cycle at the G1/S regulation point on DNA damage recognition (if it holds the cell here for long enough, the DNA repair proteins will have time to fix the damage and the cell will be allowed to continue the cell cycle). It can initiate apoptosis, the programmed cell death, if DNA damage proves to be irreparable. P53 plays a specific role in cytoplasm and nucleus. In cytoplasm it shows cellular stress. While in nucleus it shows all cellular responses like Apoptosis, Cell-cycle arrest DNA repair, Differentiation and Senescence [10] . Many cancers have the tumor suppressor p53 inactivated by mutation, making reactivation of mutant p53 with small molecules a promising strategy for the development of novel anticancer therapeutics. The oncogenic p53 mutation Y220C, which accounts for approximately 100,000 cancer cases per year [11] , creates an extended surface crevice in the DNAbinding domain, which destabilizes p53 and causes denaturation and aggregation. Aminobenzothiazole derivative, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro [12] . The present study aimed to investigate the antitumor effect of a new 2,5 disubstituted thiazole derivative in EAC-bearing mice.
MATERIALS AND METHODS

Chemicals
The following chemicals was used in the  synthesis  of  thiazole  derivative:  2-Hydroxynaphthaldehyde,  2,3-dihydroxybenzaldehyde, thiosemi carbazide ,pchloroacetophenone, bromine, ethyl acetoacetate, piperidine,glacial acetic acid, ethanol (100%), DMSO, propidium iodide (PI )stock solution were purchased from Acros Organics (Geel, Belgium).phosphate buffer saline was purchased from Biowest companyEgypt. ribonuclease I and 5-fluorouracil (5-FU) were purchased from Sigma-Aldrich (R&D system,USA). Biochemical kits were purchased from Spinreact Company. Antioxidant kits were purchased from Biodiagonistic CompanyEgypt.
Synthesis of the Compounds
A new Compound of thiazole derivative was prepared in the faculty of science, Port Said University and was taken abbreviation (TD1) this compound is:
Synthesis of Thiosemicarbazone Derivatives (IV&V)
In a 150 ml measuring flask, 2,3-dihydroxybenzadehde (2.01 mol) (II) and glacial acetic acid (25 ml) were added to the thiosemicabazide (1.01 mol) (I). The reaction mixture was heated under reflux for 2 hrs., after cooling , the contents were quenched with cold water. Solid products were collected after filtration, washing with water, dried and recrystallized with suitable solvent to give thiosemicarbazone derivative (III) (Scheme 1) [13] .
Synthesis of Thiazole Derivatives (VII&VIII)
In a 250 ml measuring flask ,p-chlorophenacyl bromide (6.01 mol) (IV), fused sodium acetate (0.03 mol) and ethanol (70 ml) were added to the thiosemicarbazone derivatives (III) (0.01 mol).The reaction mixture was heated under reflux for 4 hrs. after cooling, the contents were poured in to ice-water. The resulting product was filtered off, washed with water, dried and purified by recrystallization from ethanol to give (E)-3-((2-(5-(4-chlorophenyl) thiazol-2-yl) hydrazono) methyl) benzene-1, 2-diol (V) (TD1 ) (Scheme 2) [13] .
Synthesis of Potassium Salts of
Thiazole Derivatives (IX and X)
0.01 mole of thiazole derivative (V) were dissolved in 30 ml aqueous potassium hydroxide (0.03 mole) in beaker. The solution was left in open beaker for 2-3 days, till the solvent was evaporated, the solid residue is the potassium salt for the thiazole derivative (VI). (10, 25 , 50 and 100μM) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compounds for 48 hrs at 37 0C and in atmosphere of 5% CO2. After 48 hrs, cells were fixed, washed and stained for 30 min. with 0.4% (w/v) Rhodamine-B stain dissolved in 1% acetic acid. Unbounded dye was removed by washing four times with 1% acetic acid, and attached stain was recovered with Tris-EDTA buffer. Color intensity was measured in an enzyme linked immunosorbent assay (ELISA) reader. The relation between surviving fraction and drug concentration is plotted to get the survival curve of each tumor cell line after the specified time. The concentration required for 50% inhibition of cell viability (IC50) was calculated.
In vitro Study of Cytotoxicity
In vivo Study
Determination of median lethal dose (LD50)
LD50 of TD1 was determined according to Chinedu Eight mice (four mice for each compound) received the test compounds at doses 10,100,300 and 600 mg/ kg / b.w. In the first day, the animals were observed for one hour post administration and then 10 minutes every 2 hours interval for 24 hours. LD50 was calculated by the following formula:
Where, M0 = Highest dose of test substance that gave no mortality, M1 = Lowest dose of test substance that gave mortality.
Animals
150 healthy female Swiss albino mice of about 10 weeks old weighing 25-30 g were housed in polypropylene cages under standard conditions (12/12h light and dark cycle, temperature 25±4 ᵒ C, water ad libitum. The mice were maintained according to guidelines approved by Animal Ethical Committee at faculty of science, Zagazig University.
Tumor model
Ehrlich ascites carcinoma (EAC) bearing mice were firstly obtained from National Cancer Institute (NCI), Cairo. EAC were injected intraperitoneally once at the first day of experiment and were allowed to grow in the peritoneal cavity of mouse for ten days.
Experimental design
Mice were randomly divided into four groups (15 mice per group) as follows: - In the eleventh day, mice were anesthetized and blood was collected in EDTA-tube by retro orbital plexus using capillary tube, and then stored at -20°C until using. In addition, blood without anticoagulant was collected in plain tube and left for 10 minutes in water bath at 37 ᵒ C, then centrifuged for serum separation. After sacrificing of mice, Ehrlich ascetic fluid was collected for determining the viability of cells, the expression of p 53 and cell cycle analysis. Finally, liver and kidney samples were collected in saline containing jars for estimation of antioxidant status and small pieces were fixed in 10% formalin for histological study. Seven mice per each group were left till death to determine the mean survival time (MST) and increase in life span percentage (%ILS) (Fig. 1). 
Evaluation of Tumor weight
The weight of mice was estimated before and after withdrawal of EAC fluid and the deference is the increase in weight and expressed in grams.
Evaluation of Tumor volume
The volume of the EAC was detected by measuring tube in milliliters (ml) [10] .
Determination of cell viability
100 µl of Ehrlich ascites cells were stained with trypan blue for 15 minutes and the number of viable cells were counted using homocytometer according to the following formula;
Number of cells / ml = average × 25 ×10 
Evaluation of Hematological parameters
Complete blood count was performed using automated blood analyzer (Mindray BC2800, UK).
Evaluation of Biochemical parameters
Alanine transaminase (ALT),aspartate transaminase (AST) activities and the concentration of albumin, ,total bilirubin, urea, creatinine, cholesterol and triacylglycerol in serum were determined by colorimetric methods according to manufacturer's instructions (Spinreact,Spain) using semiautomated biochemistry analyzer (Robonik,india).
Evaluation of antioxidant parameters
The activity of Super oxide dismutase (SOD), Catalase (CAT) and reduced glutathione (GSH) and malondialdehyde (MDA) levels were determined by commercial kits (Biodiagonistics, Egypt) according to manufacturer's instructions.
Histological study
Liver and kidney tissues were fixed in 10% formaline, then sectioned in paraffin wax and examined under light microscope after staining with Hematoxylin and eosin.
Statistical Analysis
Statistical analysis was carried out using SPSS program version 14. Data were expressed as mean ± SE. Student (t) test and One-way ANOVA test were performed to detect the significance variation between test groups and control. 
Results of In vitro Cytotoxicity
Cell lines and IC50 values were determined as showing in Table 1 . 
LD 50 of TD1
In vivo toxicity study revealed that LD 50 of TD1 was recorded at 450 mg/kg.
Dose Response Curve
According to dose response curve as shown in Fig. 3 the effective dose of TD1 against EAC was recorded at 5 mg/kg because it is the lowest dose that cause the best inhibition.
The effect of Test Compounds (TD1) on Tumor Volume, Viability of EAC Cells and Life Span Prolongation
The number of viable EAC cells decreased by 90.6% (P < 0.001) after administration of TD1, when compared to EAC control group. Moreover, the percent increase in life span reached 40.66% (P<0.01) in the group which received TD1 compared to EAC control group, Table 2 .
The Effect of TD1 on Hematology
As shown in Table 3 , RBCs count was increased in TD1 groups by 15% compared to EAC control group, while hemoglobin concentration was decreased in TD1 group by 9% compared to EAC control group. In addition, administration of TD1 raised WBCs count by 178% compared to EAC control group (Table 3) .
The Effect of TD1 on Biochemical Parameters
Results of the present study demonstrated that the liver activities of AST and ALT were increased in EAC -bearing mice when compared to normal group. It was found that EAC led to some liver dysfunction. The elevation of liver enzymes is an index of impaired liver functions due to cancer as observed in EAC group. It was found that Ehrlich carcinoma induced a rise in MDA level which was associated with impaired hepatic function, as evidenced by increased serum activities of AST and ALT. The level of liver enzymes increased in serum of EAC -bearing mice indicating general toxicity found that EAC mice exhibited raised activities of liver enzymes such as AST, ALT, due to hepatocellular damages. Administration of TD1 decreased ALT concentration by 6% compared to control group. So, Administration of TD1 was slightly decreased AST concentration by 0.7% compared to control group (Table 4) . 
The Effect of TD1 on the Oxidative Status in Liver
Catalase, GSH and SOD levels are increased in EAC control group comparing with normal control group. Normalization of these changes was determined after treatment with TD1 at dose [5 mg/kg (P<0.05). While MDA was increased in EAC control group and lowered in drug group demonstrating the potential of TD1 as antioxidant agents as shown in Table 5 .
Results of Histology
It was found that the histological architecture of liver and kidney tissues in mice which received EAC only, interrupted severely while mice which treated with TD1 after EAC inoculation demonstrated an improvement in the histological characteristics of liver and kidney tissues as shown in Figs. [4] [5] [6] [7] [8] [9] [10] [11] .
Result of Cell Cycle Analysis
The percent of aneuploid cells in EAC control group increased compared to TD1 treated group, while the percent of diploid cells in TD1 treated groups increased compared to EAC control group as shown in Table 5 .
The Effect of TD1 on the Expression of P 53 in Ehrlich Cells
The expression of P 53 in mice received TD1, increased by 84% compared to EAC control group as shown in Fig. 12 . 
DISCUSSION
In this study we try to prove the efficacy of new compound of thiazole derivative as anti-tumor agents. Firstly we examine its efficacy towards human cancer cell lines and the experiment gave a good IC 50 results. Secondly we examine the efficacy of the new compound on EAC bearing mice through in vivo research which gave also excellent results which support the in vitro results. EAC is appeared firstly as a spontaneous murine mammary adeno-carcinoma [14] . It can form ascetic tumor in mice, so it is used frequently to study the antitumor efficacy of many compounds .In the present experiment increase in body weight, ascitic tumor volume, tumor weight and tumor cell count were observed in EAC control. Treatment of EAC tumor bearing mice with TD1 at the doses 5 mg/kg significantly decreased the body weight, tumor volume, tumor weight, and viable tumor cell count and increased the non-viable tumor cell count.
These results indicate either a direct cytotoxic effect of TD1 on tumor cells or an indirect local effect, which may involve macrophage activation and vascular permeability inhibition. In the present study TD1 significantly increases the life span of the EAC treated mice. Review of literature confirm that increase in life span of tumor bearing mice, decrease in tumor volume and viable cell count, and elevation of non-viable cell count is a evidences for the efficacy of any antitumor agents [15] and TD1 achieve this criterion. The major problems encountered in cancer chemotherapy are myelo suppression and anemia, which are mainly because of iron deficiency, either due to hemolytic or myelopathic conditions finally leads to reduction in RBC count or hemoglobin content. Similarly, in the present study reduced hemoglobin, RBC count and WBC count was observed in EAC control group, however RBCs count was increased in TD1groups by 15% compared to EAC control group which supports its reduced myelotoxicity and increased hematopoietic protecting activity and free radical scavenging activity, while hemoglobin concentration was decreased in TD1 group by 9% as compared to EAC control group. In addition, administration of TD1 raised WBCs count by 178% as compared to EAC control group.
Values of SGPT, SGOT, and ALb were elevated in the EAC control group but lowered in drug groups. TGL also was lowered in drug group.TD1 treatment also decreased the levels of MDA and raised the values of GSH; Catalase and SOD .These results prove the cytotoxic efficacy of TD1 on tumor cells.
Also in this research, a decrease in SOD, CAT and GSH and increase in MDA levels were noticed in EAC bearing mice.TD1 treatment prevent the decrease of antioxidant levels and rise in MDA levels in EAC bearing mice which prove the potency of TD1 in protecting against oxidative stress by normalization of antioxidants values in EAC bearing mice. lowering in antioxidants and raising in MDA is assign of cancer . Flow cytometric analysis shows that Arrest of cell cycle mostly occur in S phase then lead to apoptosis, because the aneuploid ratio is permanently and strongly relate with S phase which produce proliferation this may indicate that TD1 interfere with DNA replication.
The histopathology inspection of the liver & kidney of EAC control mice has shown many abnormalities in comparing with normal one, as congested central vein, exfoliated Epithelial cells , congested Sinusoids and Mitotic figures, as a result of cytotoxicity of the tumor. Modulation of the above mentioned effects which have been noticed in TD1 treated mice proved the strong antioxidant and hepatoprotective effects of the compound.
Flow cytometric examination of P 53 showed increased percentage of the positive population in treated group than control group (approximately double increase) which supported the hypothesis of efficacy of TD1 as apoptosis inducer.
CONCLUSION
It was concluded that TD1 have a potent antitumor activity against Ehrlich ascites
